Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NYSE:RDY) on Tuesday reported the re-launch of its US Food and Drug Administration (USFDA) approved over-the-counter (OTC) Famotidine Tablets USP in 10 mg and 20 mg in the US antacids market.
The company's OTC Famotidine Tablets USP in 10 mg and 20 mg is the store-brand equivalent of Johnson & Johnson's Original Strength and Maximum Strength Pepcid AC. This launch will fulfil an important therapy in Antacids market due to Ranitidine withdrawal. The OTC Famotidine Tablets USP, 10 mg and 20 mg, are available in multiple pack sizes to allow consumers a variety of purchasing options.
According to the company, the OTC Famotidine Tablets USP in 10 mg and 20 mg are acid reducers that prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.
For the most recent 12 months ending in August 2020, the Pepcid AC brand and generic had US sales of about USD211m, according to IRi.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical